# A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)

> **NCT00818675** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 80 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Lead-In Ridaforolimus
- **DRUG:** Comparator: Blinded Ridaforolimus
- **DRUG:** Comparator: Blinded Placebo

## Key facts

- **NCT ID:** NCT00818675
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2015-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00818675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00818675, "A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00818675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*